Literature DB >> 11592086

Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154.

L E Haswell1, M J Glennie, A Al-Shamkhani.   

Abstract

We describe the construction of a novel soluble dodecameric form of CD154 (CD40 ligand) that is more effective than trimeric tCD154 in triggering B cell activation. Dodecameric surfactant protein (SP)-D-CD154 was more potent than tCD154 in inducing B cell proliferation over a wide range of concentrations. At saturating concentrations, the level of proliferation triggered by SP-D-CD154 was fourfold higher than that achieved with tCD154. Moreover, stimulation with dodecameric CD154 induced higher levels of the costimulatory molecules ICAM-1 and CD86. The higher activity of dodecameric CD154 when compared to trimeric CD154 is unlikely to be due to differences in their avidity for CD40, since both forms bound to CD40 strongly. Therefore, the extent of receptor clustering directly regulates signaling by CD40.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592086     DOI: 10.1002/1521-4141(2001010)31:10<3094::aid-immu3094>3.0.co;2-f

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  41 in total

1.  Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Authors:  Saravana K Kanagavelu; Victoria Snarsky; James M Termini; Sachin Gupta; Suzanne Barzee; Jacqueline A Wright; Wasif N Khan; Richard S Kornbluth; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells.

Authors:  Isabell Lang; Simone Füllsack; Agnes Wyzgol; Andrea Fick; Johannes Trebing; José Antonio Carmona Arana; Viktoria Schäfer; Daniela Weisenberger; Harald Wajant
Journal:  J Biol Chem       Date:  2015-12-31       Impact factor: 5.157

3.  Multivalent recombinant proteins for probing functions of leucocyte surface proteins such as the CD200 receptor.

Authors:  Despina Voulgaraki; Rita Mitnacht-Kraus; Michelle Letarte; Mildred Foster-Cuevas; Marion H Brown; A Neil Barclay
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

4.  Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.

Authors:  Hyun-Jung An; Young Jin Kim; Dong Hyun Song; Beom Suk Park; Ho Min Kim; Ju Dong Lee; Sang-Gi Paik; Jie-Oh Lee; Hayyoung Lee
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

5.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 6.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 7.  Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.

Authors:  Richard S Kornbluth; Mariusz Stempniak; Geoffrey W Stone
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

8.  Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity.

Authors:  Sumita Ganguly; Jinyan Liu; Vinod B Pillai; Robert S Mittler; Rama Rao Amara
Journal:  Vaccine       Date:  2009-11-26       Impact factor: 3.641

Review 9.  Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics.

Authors:  Sachin Gupta; James M Termini; Saravana Kanagavelu; Geoffrey W Stone
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.